Back to Search
JOSE LUTZKY, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1235127929IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
ME43799(FL)
Education
OTHER
Class of 1980
Research & Publications (12)
A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
PMID 19307996·J Immunother·2009
3-trial
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
PMID 19622094·Br J Haematol·2009
3-trial
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
PMID 19104936·Dig Dis Sci·2009
5-case
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
PMID 18510589·Pigment Cell Melanoma Res·2008
5-case
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
PMID 18281670·J Clin Oncol·2008
3-trial
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
PMID 17010047·Br J Haematol·2006
3-trial
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.
PMID 16379038·Invest New Drugs·2006
3-trial
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.
PMID 16034306·Melanoma Res·2005
5-case
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
PMID 15953004·Br J Haematol·2005
3-trial
Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
PMID 10649247·Cancer·2000
3-trial
Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
PMID 10637253·J Clin Oncol·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1475 NW 14TH AVE
MIAMI, FL 33125 - Phone
- (305) 689-6500
Quick Facts
- NPI
- 1235127929
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 12
Are you this provider?
Claim Your Profile